Tags

Type your tag names separated by a space and hit enter

Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia.
J Lipid Res. 2000 May; 41(5):727-33.JL

Abstract

Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense LDL are more atherogenic than large, buoyant LDL. LDL apheresis is a potent therapeutic modality to lower elevated LDL-cholesterol. It is unknown whether such therapy induces a shift in the LDL subtype distribution. In this study we evaluated the influence of LDL apheresis on the LDL subtype distribution in patients with CHD and familial hypercholesterolemia (FH, n = 22), combined hyperlipidemia (CHLP, n = 6), or Lp[a]-hyperlipoproteinemia (Lp[a]-HLP, n = 4) regularly treated by LDL apheresis (immunoadsorption (n = 14), HELP apheresis (n = 8), dextran sulfate adsorption (n = 7), cascade filtration (n = 3)). On the basis of 6 LDL subfractions (d 1.020;-1.057 g/mL) isolated by density gradient ultracentrifugation the LDL-density profile was determined in each patient before and after apheresis. There was a relative increase of LDL-subfractions 1, 2, and 3 (P < 0.01, P < 0. 05, and P < 0.01, respectively) and a concomitant decrease of LDL subfractions 5 and 6 (P < 0.05) after apheresis. Subgroup analysis indicates that the degree of the small, dense LDL reduction was much more prominent in patients with CHLP compared to patients with FH or Lp[a]-HLP, whereas the type of apheresis technique had no effect. The extent of small, dense LDL reduction correlated with the preapheresis concentrations of small, dense LDL and triglycerides but not with the extent of triglyceride reduction.We conclude that LDL apheresis not only decreases LDL mass, but also improves LDL-density profile, particularly in patients with CHLP.

Authors+Show Affiliations

Department of Internal Medicine II, Klinikum Grosshadern, University of Munich, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10787433

Citation

Schamberger, B M., et al. "Influence of LDL Apheresis On LDL Subtypes in Patients With Coronary Heart Disease and Severe Hyperlipoproteinemia." Journal of Lipid Research, vol. 41, no. 5, 2000, pp. 727-33.
Schamberger BM, Geiss HC, Ritter MM, et al. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J Lipid Res. 2000;41(5):727-33.
Schamberger, B. M., Geiss, H. C., Ritter, M. M., Schwandt, P., & Parhofer, K. G. (2000). Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. Journal of Lipid Research, 41(5), 727-33.
Schamberger BM, et al. Influence of LDL Apheresis On LDL Subtypes in Patients With Coronary Heart Disease and Severe Hyperlipoproteinemia. J Lipid Res. 2000;41(5):727-33. PubMed PMID: 10787433.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. AU - Schamberger,B M, AU - Geiss,H C, AU - Ritter,M M, AU - Schwandt,P, AU - Parhofer,K G, PY - 2000/4/29/pubmed PY - 2000/8/1/medline PY - 2000/4/29/entrez SP - 727 EP - 33 JF - Journal of lipid research JO - J. Lipid Res. VL - 41 IS - 5 N2 - Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense LDL are more atherogenic than large, buoyant LDL. LDL apheresis is a potent therapeutic modality to lower elevated LDL-cholesterol. It is unknown whether such therapy induces a shift in the LDL subtype distribution. In this study we evaluated the influence of LDL apheresis on the LDL subtype distribution in patients with CHD and familial hypercholesterolemia (FH, n = 22), combined hyperlipidemia (CHLP, n = 6), or Lp[a]-hyperlipoproteinemia (Lp[a]-HLP, n = 4) regularly treated by LDL apheresis (immunoadsorption (n = 14), HELP apheresis (n = 8), dextran sulfate adsorption (n = 7), cascade filtration (n = 3)). On the basis of 6 LDL subfractions (d 1.020;-1.057 g/mL) isolated by density gradient ultracentrifugation the LDL-density profile was determined in each patient before and after apheresis. There was a relative increase of LDL-subfractions 1, 2, and 3 (P < 0.01, P < 0. 05, and P < 0.01, respectively) and a concomitant decrease of LDL subfractions 5 and 6 (P < 0.05) after apheresis. Subgroup analysis indicates that the degree of the small, dense LDL reduction was much more prominent in patients with CHLP compared to patients with FH or Lp[a]-HLP, whereas the type of apheresis technique had no effect. The extent of small, dense LDL reduction correlated with the preapheresis concentrations of small, dense LDL and triglycerides but not with the extent of triglyceride reduction.We conclude that LDL apheresis not only decreases LDL mass, but also improves LDL-density profile, particularly in patients with CHLP. SN - 0022-2275 UR - https://www.unboundmedicine.com/medline/citation/10787433/Influence_of_LDL_apheresis_on_LDL_subtypes_in_patients_with_coronary_heart_disease_and_severe_hyperlipoproteinemia_ L2 - http://www.jlr.org/cgi/pmidlookup?view=long&amp;pmid=10787433 DB - PRIME DP - Unbound Medicine ER -